Apellis Pharmaceuticals Inc (APLS) — Cash Flow-to-Debt Ratio
Apellis Pharmaceuticals Inc (APLS) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of $-60.97 Million could theoretically repay 0% of its total liabilities ($667.61 Million) in one year. Check Apellis Pharmaceuticals Inc (APLS) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apellis Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Apellis Pharmaceuticals Inc across 13 annual periods. Also explore Apellis Pharmaceuticals Inc total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Apellis Pharmaceuticals Inc (2013–2025)
Year-by-year debt coverage analysis for Apellis Pharmaceuticals Inc. For market capitalisation and broader financial context, see APLS market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | $45.33 Million | $705.11 Million | ▲ +148.0% |
| 2024 | -0.13x | $-87.87 Million | $656.51 Million | ▲ +86.6% |
| 2023 | -1.00x | $-594.74 Million | $594.21 Million | ▼ -15.0% |
| 2022 | -0.87x | $-513.75 Million | $590.35 Million | ▼ -5.6% |
| 2021 | -0.82x | $-563.13 Million | $683.10 Million | ▼ -288.3% |
| 2020 | -0.21x | $-160.49 Million | $756.01 Million | ▲ +64.3% |
| 2019 | -0.59x | $-211.13 Million | $355.02 Million | ▲ +80.7% |
| 2018 | -3.08x | $-131.24 Million | $42.56 Million | ▼ -119.6% |
| 2017 | -1.40x | $-46.60 Million | $33.19 Million | ▲ +80.4% |
| 2016 | -7.15x | $-26.00 Million | $3.64 Million | ▼ -21.3% |
| 2015 | -5.89x | $-18.86 Million | $3.20 Million | ▲ +35.9% |
| 2014 | -9.20x | $-9.95 Million | $1.08 Million | ▼ -80.7% |
| 2013 | -5.09x | $-3.44 Million | $676.96K | — |